Senior officials at the Food and Drug Administration (FDA) were reportedly surprised by new guidelines allowing certain nicotine products, including flavored vapes, to enter the U.S. market without full regulatory review. This abrupt policy change, which was published online shortly before the resignation of former Commissioner Marty Makary, has raised significant concerns among FDA staff who were not consulted prior to the announcement. The guidelines mark a shift from the FDA's long-standing requirement for scientific verification of health benefits before introducing new products. Mitch Zeller, a former FDA tobacco director, criticized the process, questioning whether the decision was influenced by external pressures from industry lobbyists. The new guidelines allow for 'enforcement discretion,' meaning certain unauthorized products can be sold without immediate regulatory action. This could potentially open the market to a variety of flavored vapes that were previously rejected due to concerns about their appeal to youth. While the FDA aims to focus enforcement on products with features appealing to children, the implications of this shift could disproportionately benefit larger tobacco companies, leaving smaller firms at a disadvantage. The evolving landscape of vaping regulation continues to raise questions about public health and industry influence.